Medical aesthetics company Sientra, Inc., announces that it has begun commercial shipping of its Viality with AuraClens fat transfer system. The company has also released the preliminary results from its ongoing, multicenter, long-term volume retention clinical study with Viality. These preliminary results show more than 80% volume retention at both the 3- and 6-month timepoints, according to Sientra officials.

“The promising results showcased in this preliminary data mirrors what I am seeing clinically with the patients I have treated with Viality to-date,” says board-certified plastic surgeon and clinical study investigator Sachin M. Shridharani, MD, FACS. “Fat transfer has been gaining popularity for the past decade, and with Viality, Sientra has not only contributed to an unmet market need though superior fat retention rates, but allows me to offer my patients predictable outcomes, with the natural results they are looking for.”

Based on the preliminary results, with 68 patients enrolled, the clinical study shows more than 80% volume retention at both 3- and 6-months post breast augmentation and reconstruction. In addition, volume changes from 3 to 6 months were on average only 3.59%, indicating the long-term viability of fat transfer when using Viality.

“Sientra is known for elevating industry standards through innovation and unmatched product quality,” says Ron Menezes, president and CEO of Sientra. “This research allows us to best equip surgeons with what they need to generate the best outcomes for their patients.”

Menezes adds, “We have experienced a significant demand for the product in presales alone and look forward to putting Viality in the hands of our plastic surgeon customers as we commence commercial shipping. We anticipate that when the study is completed, the results of this first-of-its-kind study will establish a new standard for evidence in fat transfer.”

Sientra will continue to develop the data within the ongoing clinical study.